<DOC>
	<DOCNO>NCT02592018</DOCNO>
	<brief_summary>This single-arm , open-label study , examine effect secukinumab immunologic genetic environment within psoriatic lesion .</brief_summary>
	<brief_title>Immunologic Response Secukinumab Plaque Psoriasis</brief_title>
	<detailed_description>Quantitative analysis immunologic change immune cell population perform secukinumab treatment 15 patient week 2 , 4 , 12 compare baseline week 0 . The immunologic profile psoriasis patient also compare healthy control skin surgical discard specimen ( n=10 ) . The number differentially express gene cell population quantify RNA-seq week 2 , 4 , 12 secukinumab compare baseline .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Ability provide write informed consent comply protocol . 2 . At least 18 year age . 3 . Diagnosis predominately plaque psoriasis least 6 month prior enrollment . 4 . Subject consider candidate phototherapy systemic therapy 5 . PASI ≥ 12 6 . PGA ≥ 3 7 . Subject negative Quantiferon Gold , positive undergoes CXR . If CXR negative , subject initiate prophylactic therapy isoniazid course 9 month one month therapy complete prior first dose secukinumab . 8 . Subject unlikely conceive ( male , postmenopausal , use adequate oral contraceptive therapy IUD ) . 9 . Physical exam within clinically acceptable limit . 1 . Subject unable provide write informed consent comply protocol . 2 . Subject young 18 year age . 3 . Subject predominately nonplaque form psoriasis . 4 . Subject mild psoriasis ( PASI &lt; 12 PGA &lt; 3 ) candidate phototherapy systemic treatment . 5 . Subject druginduced psoriasis . 6 . Subject current , history , severe psoriatic arthritis well control current therapy . 7 . Subjects serum creatinine level exceed 176.8 μmol/L ( 2.0 mg/dl ) . 8 . Screening total white blood cell ( WBC count ) &lt; 2,500/μl , platelet &lt; 100,000/μl , neutrophil &lt; 1,500/μl , hemoglobin &lt; 8.5 g/dl . 9 . Evidence active tuberculosis infection define positive QuantiFERON TBGold test ( QFT ) positive chest Xray screening , untreated latent tuberculosis define positive QFT negative chest Xray without prophylactic therapy isoniazid course 9 month one month therapy complete prior first dose secukinumab . 10 . History ongoing , chronic recurrent infectious disease include past medical history record HIV , hepatitis B hepatitis C. 11 . Subjects possess diagnosis , investigator 's opinion , preclude him/her safely participate study interfere evaluation subject 's psoriasis . 12 . History know suspect intolerance ingredient investigational study product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>